Anti-Chikungunya E1 Protein [Clone CHK-166] — Purified in vivo GOLD™ Functional Grade
Anti-Chikungunya E1 Protein [Clone CHK-166] — Purified in vivo GOLD™ Functional Grade
Product No.: C468
Clone CHK-166 Target Chikungunya E1 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names CHIKV, Chikungunya virus, VLPs, Chikungunya virus-like particles Isotype Mouse IgG2c κ Applications ELISA , FC , in vivo , N |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Dilution Buffer Immunogen Chikungunya E1 protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level <1.0 EU/µg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Additional Applications Reported In Literature ? N
ELISA FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity CHK-166 activity is directed against CHIKV E1. Background Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics globally and has been declared a notable disease by the CDC1,2. CHIKV is an enveloped virus with an 11.8-kb single-stranded, positive-sense RNA genome with two open reading frames3,4. There are three main genotypes, having 95.2 to 99.8% amino acid identity: Asian, West African, and East/Central/South African (ECSA). The mature CHIKV virion is comprised of a nucleocapsid protein C and two glycoproteins, E1 and E25. E1 participates in virus fusion. E2 functions in attachment to cells. E1 and E2 form 80 trimeric spikes on the virus surface6.
CHK-166 is a neutralizing monoclonal antibody (MAb) that provides complete protection against lethality as prophylaxis in Ifnar−/− mice5. It was generated by infecting adult Irf7−/− C57BL/6 mice with the La Reunion 2006 OPY-1 strain of CHIKV (CHIKV-LR) and boosting with recombinant CHIKV E2 protein or infectious CHIKV-LR. Myeloma cell-splenocyte fusions were screened for binding to CHIKV-LR infected cells and the resulting MAb was cloned for analysis. Neutralization escape variants were generated to map the CHK-166 epitope5. CHK-166 recognizes amino acids on domain II of E1, adjacent to the conserved fusion loop. All escape mutants had a single K61T mutation in the E1 protein. CHK-166 inhibits CHIKV infection in cell culture in a post-attachment neutralization assay5. CHK-166 also protects 63% of mice from death when a single dose is administered 24 h after CHIKV infection. If both CHK-166 and CHK-152 are administered post-infection in mice, then viral resistance is prevented and the treatment window is extended5. Additionally, combination CHK-152/CHK-166 MAb therapy in rhesus macaques reduces viral infection and spread, neutralizes reservoirs of infectious virus, and does not produce escape viruses7. Antigen Distribution E1 is expressed on the surface of CHIKV. Research Area Category B Pathogens . Chikungunya . Infectious Disease . Viral . IVD Raw Material Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. CHK-166 is a neutralizing monoclonal antibody targeting the E1 glycoprotein of chikungunya virus (CHIKV) that is used in in vivo mouse studies primarily to provide protection against CHIKV infection, assess resistance and viral escape, and study combination antibody therapies. Key details on its use in mouse models include:
Summary Table: Use of CHK-166 in Mouse Studies
Essential context: Use of CHK-166 in vivo is central for evaluating antibody-mediated neutralization, resistance mechanisms, and potential therapeutic regimens for CHIKV in mouse models deficient in interferon response, mirroring severe disease. The correct storage temperature for sterile packaged clone CHK-166 (Anti-Chikungunya virus E1 Antibody) is between -10°C and -25°C. This recommendation comes directly from the manufacturer, Merck Millipore, which specifies:
For handling upon receipt, the manufacturer recommends centrifuging the vial before opening and aliquoting the solution if needed. Additional details from related sterile antibody products confirm:
Other storage guidelines (e.g., USP, general antibody handling) do not override the manufacturer-specific instructions for CHK-166. Always prioritize the product datasheet for critical storage details. Based on research findings, CHK-166 is commonly used in combination with several other monoclonal antibodies in chikungunya virus (CHIKV) studies, particularly for therapeutic applications. Primary Combination PartnersCHK-152 represents the most frequently studied combination partner with CHK-166. This pairing has been extensively evaluated in multiple therapeutic contexts, showing remarkable efficacy when administered together. The CHK-166 plus CHK-152 combination demonstrated complete protection against lethality when given as prophylaxis and maintained high protective efficacy even when treatment was delayed up to 60 hours post-infection. CHK-102 serves as another important combination partner with CHK-166. Research has shown that CHK-102 combined with CHK-152 or CHK-166 combined with CHK-152 provided equivalent protective effects, with both combinations achieving 100% survival rates when administered 24 hours after infection in highly susceptible mouse models. Mechanistic ConsiderationsThe combination approach with CHK-166 addresses a critical challenge in monoclonal antibody therapy: viral resistance emergence. When CHK-166 is used alone, it can select for specific escape mutations, particularly the E1-K61T mutation in the viral envelope protein. However, combining CHK-166 with other antibodies like CHK-152 prevents the emergence of such resistance variants and extends the therapeutic window significantly. Comparative ContextWhile CHK-166 is primarily studied alongside CHK-152 and CHK-102, other notable antibodies in the chikungunya research field include CHK-263, CHK-124, and CHK-265. CHK-263, in particular, has been characterized for its unique binding properties, as it binds across both E1 and E2 proteins similar to CHK-166, though their specific epitopes differ. The literature consistently demonstrates that CHK-166's therapeutic potential is maximized when used in combination therapy rather than as a monotherapy, with CHK-152 being its most validated and effective partner in preclinical studies. CHK-166 is a neutralizing monoclonal antibody that has demonstrated significant therapeutic potential against chikungunya virus (CHIKV) in multiple scientific studies. The key findings from the literature reveal important insights about its mechanism of action, efficacy, and limitations. Target and Mechanism of ActionCHK-166 specifically targets the E1 protein of chikungunya virus, recognizing amino acids on domain II of E1 adjacent to the conserved fusion loop. The E1 protein plays a crucial role in virus fusion, making it an important therapeutic target. This monoclonal antibody works through post-attachment neutralization, inhibiting CHIKV infection in cell culture after the virus has already attached to host cells. Therapeutic EfficacyProphylactic Protection: CHK-166 provides complete protection against lethality when used as prophylaxis in Ifnar?/? mice, demonstrating its potential as a preventive treatment. Post-Exposure Treatment: When administered as a single dose 24 hours after CHIKV infection, CHK-166 protects 63% of mice from death. This indicates its therapeutic window extends beyond prophylactic use, though with reduced efficacy compared to pre-exposure administration. Combination Therapy Benefits: The most significant findings emerge from combination therapy studies. When CHK-166 is administered together with CHK-152 (another neutralizing monoclonal antibody), several important benefits are observed:
Neutralization Escape and ResistanceA critical finding involves the development of resistance mechanisms. Under immune pressure from CHK-166, the virus consistently develops an E1-K61T mutation in cell culture. This mutation represents the dominant escape variant selected when CHIKV is exposed to CHK-166 alone. The significance of this escape mutation was further investigated by engineering it into infectious cDNA clones of CHIKV. These studies revealed that individual mutations might be attenuating and could potentially revert to wild-type sequences in the absence of antibody pressure. Clinical Development ContextThe development of CHK-166 involved infection of adult Irf7?/? C57BL/6 mice with the La Reunion 2006 OPY-1 strain of CHIKV, followed by boosting with recombinant CHIKV E2 protein or infectious CHIKV. This methodical approach to antibody generation has contributed to its specificity and efficacy profile. Implications for Treatment StrategyThe research findings strongly support combination monoclonal antibody therapy over single-agent treatment. The ability of combination CHK-152/CHK-166 therapy to prevent escape virus generation while extending the therapeutic window represents a significant advancement in chikungunya virus treatment strategies. This approach addresses one of the major challenges in antiviral therapy – the development of resistance – while maintaining therapeutic efficacy across a broader treatment timeline. The studies collectively demonstrate that CHK-166 represents a promising therapeutic agent for chikungunya virus infection, particularly when used in combination with complementary neutralizing antibodies that target different viral epitopes. References & Citations1. Barrera, R., Hunsperger, E., Lanciotti, RS. et al. Preparedness and response for chikungunya virus introduction in the Americas. Pan American Health Organization; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases. 2011.
2. Silva, JVJ Jr., Ludwig-Begall, LF., Oliveira-Filho, EF. et al. Acta Trop. 188:213-224. 2018. 3. Powers, AM., Brault, AC., Tesh, RB. et al. J. Gen. Virol. 81:471–479. 2000. 4. Arankalle, VA., Shrivastava, S., Cherian, S. et al. J. Gen. Virol. 88:1967–1976. 2007. 5. Pal, P., Dowd, KA., Brien, JD. et al. PLoS Pathog. 9(4):e1003312. 2013. 6. Mukhopadhyay, S., Zhang, W., Gabler, S. et al. Structure. 14(1):63-73. 2006. 7. Pal, P, Fox, JM., Hawman, DW. et al. J Virol. 88(15):8213-8226. 2014. Technical Protocols   N Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
